Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION In a 505(b)(2) program relying on literature plus a bridging study, scientific-advice briefing book is the evidence after a DSMB note on an imbalance that is not yet a signal. Pediatric-plan strategist has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy close using scientific-advice briefing book.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. A DSMB note on an imbalance that is not yet a signal is noise around an already-controlled Clinical and Evidence Strategy process in a 505(b)(2) program relying on literature plus a bridging study, given scientific-advice briefing book. 2. A DSMB note on an imbalance that is not yet a signal is the event in scientific-advice briefing book that forces Proceed under protocol for pediatric-plan strategist under Pharma & Life Sciences. 3. Scientific-advice briefing book shows a one-file miss after a DSMB note on an imbalance that is not yet a signal, not a Clinical and Evidence Strategy program failure. 4. Scientific-advice briefing book cannot decide to drop a secondary yet after a DSMB note on an imbalance that is not yet a signal; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

ANALYSIS REQUIRED 1. Check whether scientific-advice briefing book supports the labeled claim pediatric-plan strategist would keep. 2. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 3. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a DSMB note on an imbalance that is not yet a signal. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read scientific-advice briefing book against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (scientific-advice briefing book after a DSMB note on an imbalance that is not yet a signal). If scientific-advice briefing book cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. Do not invent missing evidence a 505(b)(2) program relying on literature plus a bridging study does not have.